bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
FIB

Order Name:
Fibrinogen*

 
Useful For:
Detecting increased or decreased fibrinogen (factor 1) concentration of acquired or congenital origin.

Monitoring severity and treatment of disseminated intravascular coagulation and fibrinolysis.
 
Methodology:
Clotting assay
 
AliasesName:
Factor I
Fibrinogen(COAG)
 
 
 
 
Test Code:
FIB

Order Name:
Fibrinogen*

 
Collection Specimen Or Container:
Blood/ Sodium citrate tube (Sodium Citrate 3.2% anticoagulant, Blue top) 3 mL, 1 tube
 
Specimen Testing Type:
Citrate plasma, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: Hemoglobin >375 mg/dL will be reject.
Lipemia: Triglyceride >750 mg/dL will be reject.
Icterus: Bilirubin >21 mg/dL will be reject.
Other:
  1. Clotted specimen will be reject.
  2. Heparin >1 U/mL will be reject.
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood, Citrate blood Room temperature, 18oC to 25oC 4 hours
Plasma, Citrate blood Refrigerated, 2oC to 8oC 4 hours
Room temperature, 18oC to 25oC 4 hours
Frozen, -20oC 2 weeks
Frozen, -70oC 1 year
 
 
 
Test Code:
FIB

Order Name:
Fibrinogen*

 
Method detail:
Clotting assay
 
Schedule:
Tested Daily (24 hours)
 
Turnaround Time:
Collected specimen to report within 90 mins.
 
Performing Location:
Hematology, Laboratory Department Tel. 17254
 
Specimen Retention Time:
14 days
 
 
 
Test Code:
FIB

Order Name:
Fibrinogen*

 
 
Clinical Information:
Fibrinogen (clotting factor I) is an essential protein responsible for blood clot formation. In the final step of the coagulation cascade, thrombin converts soluble fibrinogen into insoluble fibrin strands that crosslink and form a clot.

Fibrinogen is synthesized in the liver and has a biological half-life of 3 to 5 days in the circulating plasma. Fibrinogen deficiencies can be congenital or acquired and lead to prolonged coagulation times. Isolated fibrinogen deficiency is an extremely rare inherited coagulation disorder.
 
Reference Value:
200 – 393 mg/dL
 
Interpretation:
Acquired causes of decreased fibrinogen levels include acute or decompensated intravascular coagulation and fibrinolysis (disseminated intravascular coagulation), advanced liver disease, L-asparaginase therapy, and therapy with fibrinolytic agents (eg, streptokinase, urokinase, tissue plasminogen activator).

Fibrinogen function abnormalities, dysfibrinogenemias, may be inherited (congenital) or acquired. Patients with dysfibrinogenemia are generally asymptomatic. However, the congenital dysfibrinogenemias are more likely than the acquired to be associated with bleeding or thrombotic disorders. While the dysfibrinogenemias are generally not associated with clinically significant hemostasis problems, they characteristically produce a prolonged thrombin time clotting test. Congential dysfibrinogenemias usually are inherited as autosomal codominant traits.

Acquired dysfibrinogenemias mainly occur in association with liver disease (eg, chronic hepatitis, hepatoma) or renal diseases associated with elevated fibrinogen levels.

Fibrinogen is an acute-phase reactant, so a number of acquired conditions can result in an increase in its plasma level:
  • Acute or chronic inflammatory illnesses
  • Nephrotic syndrome
  • Liver disease and cirrhosis
  • Pregnancy or estrogen therapy
  • Compensated intravascular coagulation

The finding of an increased level of fibrinogen in a patient with obscure symptoms suggests an organic rather than a functional condition. Chronically increased fibrinogen has been recognized as a risk factor for development of arterial and venous thromboembolism.
 
Clinical Reference:
  1. Manufacturer’s reagent package insert, Fibrinogen-C, HemosiIL®, Instrumentation Laboratory Company - Bedford, MA 01730-2443 (USA) and Instrumentation Laboratory SpA - V.le Monza 338 - 20128 Milano (Italy) ; 10/2015
  2. https://www.mayocliniclabs.com (Retrieved: 22 Jan 2019)